130 related articles for article (PubMed ID: 35822688)
21. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
22. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.
Li J; Gu J
Future Oncol; 2019 May; 15(14):1667-1678. PubMed ID: 31041879
[No Abstract] [Full Text] [Related]
25. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H
J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Liao G; Zhao Z; Qian Y; Ling X; Chen S; Li X; Kong FS
Front Oncol; 2021; 11():774131. PubMed ID: 35004295
[TBL] [Abstract][Full Text] [Related]
28. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
Hata A; Katakami N; Nanjo S; Okuda C; Kaji R; Masago K; Fujita S; Yoshida H; Zama K; Imai Y; Hirata Y
Lung Cancer; 2017 Sep; 111():182-189. PubMed ID: 28838391
[TBL] [Abstract][Full Text] [Related]
29. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
[TBL] [Abstract][Full Text] [Related]
30. Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.
Kawakami H; Sunakawa Y; Inoue E; Matoba R; Noda K; Sato T; Suminaka C; Yamaki M; Sakamoto Y; Kawabata R; Ishiguro A; Akamaru Y; Kito Y; Yabusaki H; Matsuyama J; Takahashi M; Makiyama A; Hayashi H; Chamoto K; Honjo T; Nakagawa K; Ichikawa W; Fujii M
Eur J Cancer; 2023 May; 184():10-20. PubMed ID: 36889037
[TBL] [Abstract][Full Text] [Related]
31. The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients.
Ancın B; Özercan MM; Yılmaz YM; Uysal S; Kumbasar U; Sarıbaş Z; Dikmen E; Doğan R; Demircin M
Turk J Med Sci; 2022 Aug; 52(4):1050-1057. PubMed ID: 36326416
[TBL] [Abstract][Full Text] [Related]
32. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
33. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
[TBL] [Abstract][Full Text] [Related]
34. The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Meta-analysis.
Ding Y; Sun C; Li J; Hu L; Li M; Liu J; Pu L; Xiong S
Scand J Immunol; 2017 Nov; 86(5):361-367. PubMed ID: 28930374
[TBL] [Abstract][Full Text] [Related]
35. Meta-analysis of the prognostic value of soluble programmed death ligand-1 (sPD-L1) in cancers.
Sun J; Hu S; Li X
Biomarkers; 2023 Sep; 28(6):477-485. PubMed ID: 37017446
[TBL] [Abstract][Full Text] [Related]
36. Plasma sPD-L1 and VEGF levels are associated with the prognosis of NSCLC patients treated with combination immunotherapy.
Dong C; Hui K; Gu J; Wang M; Hu C; Jiang X
Anticancer Drugs; 2024 Jun; 35(5):418-425. PubMed ID: 38386011
[TBL] [Abstract][Full Text] [Related]
37. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
38. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
39. PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study.
Cronin-Fenton D; Dalvi T; Movva N; Pedersen L; Hansen H; Fryzek J; Hedgeman E; Mellemgaard A; Rasmussen TR; Shire N; Hamilton-Dutoit S; Nørgaard M
Sci Rep; 2021 Aug; 11(1):16892. PubMed ID: 34413420
[TBL] [Abstract][Full Text] [Related]
40. Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.
Yu H; Brustugun OT; Ekman S; Botling J; La Fleur L; Micke P; Solberg S; Berglund A; Rivard C; Hirsch FR
Clin Lung Cancer; 2021 Jul; 22(4):e555-e562. PubMed ID: 33214079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]